|When Are All These "Fantastic" New HCV Drugs Going to be Available?
Apr 20, 2010
I am 2b geno who did go to undetectable at wk 4, but then quickly relapsed when off RBV/INF Tx. That was 3 yrs ago, and I did get a histological benefit Stage 2+ back to a 1/2, w/ normal hepatic panels. Will these new antivirals be available for a 2b .... or are they really engineered for geno 1 people? And when are they really going to be available? I'm also HIV+, but well controlled. I'm just trying looking for an approx. answer. thank you!
| Response from Dr. McGovern
You ask an excellent question - one that will interest many people who read this site.
Yes, most of the drugs are being first studied for genotype 1 infection...But now some data are emerging on the treatment of other genotypes. In fact, at the liver meetings in Europe this past week there were data shown that telaprevir, a HCV protease inhibitor that is in very advance stages of development, has very good activity against HCV genotype 2....
So hang in there...In the meantime, review your HIV medications with your doctor to be certain that they are metabolically "friendly"...I say this because you want to pay attention to risk factors for fatty liver disease (eg, insulin resistance and abnormal lipids, such as high cholesterol and triglycerides). Insulin resistance also gets in the way of treatment responses to interferon/ribavirin therapy.
Hope this is helpful to you and others.
Get Email Notifications When This Forum Updates or Subscribe With RSS
This forum is designed for educational purposes only, and experts are not rendering medical, mental health, legal or other professional advice or services. If you have or suspect you may have a medical, mental health, legal or other problem that requires advice, consult your own caregiver, attorney or other qualified professional.
Experts appearing on this page are independent and are solely responsible for editing and fact-checking their material. Neither TheBody.com nor any advertiser is the publisher or speaker of posted visitors' questions or the experts' material.